Childhood Obesity - Prevention of Diabetes Through Changed Eating Patterns

January 12, 2023 updated by: University of Aarhus

Childhood Obesity - Prevention of Diabetes Through Changed Eating Patterns (The COPE-study) - An Intervention Trial Investigating the Efficacy of Dietary Changes in Protein

The main purpose of the present study is to perform a 10 weeks dietary intervention study with a follow-up for 52 weeks in children from 7-14 years of age with overweight or obesity. In a caloric restricted and increased physical activity setting the control group will consume a low-moderate protein (15E%/day) diet whereas the intervention group will consume a higher protein (25E%/day) diet. Furthermore, the investigators want to investigate the effect of frequent follow-up after intervention.

Compared to the low-moderate protein diet, the investigators hypothesis that a diet with higher consumption of protein-containing foods will more effectively induce weight loss (a reduction in BMI-SDS) or weight maintenance in children with overweight or obesity, and improve risk factors for type 2 diabetes and Quality of Life.

Study Overview

Detailed Description

The study will be performed in collaboration with the staff of the well-established multi-component-overnight camps (Julemærkehjem) in Denmark. The multi-component-overnight camps are intensive weight loss camps to which Danish schoolchildren, from 7-14 years of age, are referred to for 10-weeks intervention focusing on healthy lifestyle, healthy eating, new habits and increased physical activity.

The primary outcome is anthropometry (BMI-SDS, fat mass, fat-free mass). Secondary outcomes are blood-tests measuring metabolic, inflammatory and liver markers and questionnaires investigating Quality of Life, Eating Behavior, Eating Habits and Disturbed Eating.

The children will be measured at baseline, 10-weeks and 52-weeks follow-up. Furthermore, participants will be invited to follow-up investigation 3 years, 5 years, 7 years and 10 years, respectively, after the intervention.

Study Type

Interventional

Enrollment (Actual)

229

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hobro, Denmark, 9500
        • Weight Loss Camp Hobro
      • Kruså, Denmark, 6340
        • Weight Loss Camp Fjordmark

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 14 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The child attends a multi-component-overnight camp in Hobro or Fjordmark between September 2020 and December 2021.
  • The child is between 7 and 14 years of age (inclusive) while attending camp.
  • At least one parent/guardian submit written and oral consent to participate with his/her child.
  • Parent/legal guardian has submitted oral and written consent to participation of their child. In case of shared custody both parents must submit written and oral consent before their child can participate in the trial.

Exclusion Criteria:

  • The child has a disease, diagnose or eating disorder that require treatment.
  • The child or parent/guardian participate in another clinical trial or plan to do so in the near future.
  • The parent/guardian do not understand the written informed consent.
  • The child or parent/guardian are unwilling to or unable to comply with the study protocol and instruction given by the study staff.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Group (CG)
Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and regular follow-up.
Experimental: Follow-up group (FUG)
Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and increased follow-up.
After leaving the camp, the children and their families with increased follow-up contact will be contacted once every month within the first 6 month and once every other month until 52-weeks follow-up (8 times total). The children and their families will be contacted by phone, facetime or skype as they prefer, within a predetermined and known timeframe. The conversation will focus on individual topics chosen by the child/parent.
Experimental: Intervention group (IG)
A higher protein diet (25E%/day) for the 10 weeks they attend the camp and increased follow-up.
After leaving the camp, the children and their families with increased follow-up contact will be contacted once every month within the first 6 month and once every other month until 52-weeks follow-up (8 times total). The children and their families will be contacted by phone, facetime or skype as they prefer, within a predetermined and known timeframe. The conversation will focus on individual topics chosen by the child/parent.
In a caloric restricted and increased physical activity setting, the control group will consume a low-moderate protein (15E%/day) diet whereas the intervention group will consume a higher protein (25E%/day) diet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Weight
Time Frame: Changes from baseline to 10 weeks and 52-weeks follow-up.
Weight will be measured in kilograms using a Bioelectric impedance
Changes from baseline to 10 weeks and 52-weeks follow-up.
Change in Height
Time Frame: Changes from baseline to 10 weeks and 52-weeks follow-up.
Height will be measured in centimeter using a fixed wall measuring tape
Changes from baseline to 10 weeks and 52-weeks follow-up.
Change in Body Mass Index (BMI)
Time Frame: Changes from baseline to 10 weeks and 52-weeks follow-up.
Weight in kilograms and height in centimeter will be combined to report BMI in kg/m^2
Changes from baseline to 10 weeks and 52-weeks follow-up.
Change in fat mass/fat free mass
Time Frame: Changes from baseline to 10 weeks and 52-weeks follow-up.
Fat mass/fat free mass will be measured using a Bioelectric impedance.
Changes from baseline to 10 weeks and 52-weeks follow-up.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in children´s well-being
Time Frame: Changes from baseline to 10-weeks and 52-weeks follow-up
Children´s well-being will be measured using the Children PedsQL4.0 questionnaire. A 5-point ordinal scale is used to score how big a problem everyday events are (the minimum value will be "never a problem" and the maximum value will be "almost always a problem"). Items are reverse-scored and linearly transformed so that higher scores indicate higher well-being.
Changes from baseline to 10-weeks and 52-weeks follow-up
Change in Eating Habits
Time Frame: Changes from baseline to 10-weeks, 22 weeks and 52-weeks follow-up.
Eating habits will be measured using the Children's Eating Habits Questionnaire-FFQ. The FFQ contains forty-three food groups clustered into thirty-six according to their nutritional profiles. On an 8-point ordinal scale children will answer how frequent they consumed different food groups (the minimum value will be "never/less than once a week" and the maximum value will be "4 or more times/week").
Changes from baseline to 10-weeks, 22 weeks and 52-weeks follow-up.
Change in Eating Behaviour
Time Frame: Changes from baseline to 10-weeks, 22 weeks and 52-weeks follow-up.
Eating Behaviour will be measured using the Child Eating Behaviour Questionnaire (CEBQ). CEBQ questions are grouped into 8 subgroups: food responsiveness (FR), enjoyment of food (EF), desire to drink (DD), satiety responsiveness (SR), slowness in eating (SE), food fussiness (FF), emotional overeating (EOE) and emotional undereating (EUE). Questions will be answered on a 5-point ordinal scale (the minimum value will be "never" and the maximum value will be "always"). Overweight and obese children will scores higher in 'food approach' subgroups (i.e. FR, DD, EF, EOE) and lower in 'food avoidant' subgroups (i.e. SR, SE, EUE, FF).
Changes from baseline to 10-weeks, 22 weeks and 52-weeks follow-up.
Loss of Control Eating (LOC) episodes
Time Frame: Will be measured three consecutive months before the intervention and three consecutive months after the intervention.
LOC eating will be measured using two questions from the Eating Disorder examination questionnaire (EDE-Q 6.0) and measured on a ratio-interval scale and 0 will be the minimum value. Recurrent LOC eating is defined by >4 LOC episodes within the past 28 days. LOC eating must be investigated over three consecutive months before evaluation.
Will be measured three consecutive months before the intervention and three consecutive months after the intervention.
Metabolic markers
Time Frame: Changes from baseline to 10 weeks and 52-weeks follow-up.
A blood test will collected to measure metabolic markers (HbA1c, urate, lipids (total, high-density lipoprotein (HDL)-, and low-density lipoprotein (LDL) cholesterol, and triglycerides), fasting plasma glucose). Units of measure will be the same in all.
Changes from baseline to 10 weeks and 52-weeks follow-up.
Liver markers
Time Frame: Changes from baseline to 10 weeks and 52-weeks follow-up.
A blood test will collected to measure liver markers (Asat, Alat, alkaline phosphatase, platlets, GGT, albumine). Units of measure will be the same in all.
Changes from baseline to 10 weeks and 52-weeks follow-up.
Inflammatory markers
Time Frame: Changes from baseline to 10 weeks and 52-weeks follow-up.
A blood test will collected to measure inflammatory markers (High-sensitive C-reactive protein (hs-CRP), Interleukin(IL)-6, IL-8, leptin, adiponectin, cluster of differentiation(CD)163, CD36, fibroblast growth factor(FGF)-21, monocyte chemoattractant protein(MCP)-1, and Growth/differentiation factor (GDF)15). Units of measure will be the same in all.
Changes from baseline to 10 weeks and 52-weeks follow-up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jens M Bruun, Professor, Aarhus University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2020

Primary Completion (Anticipated)

June 30, 2023

Study Completion (Anticipated)

December 31, 2032

Study Registration Dates

First Submitted

August 13, 2020

First Submitted That Met QC Criteria

August 18, 2020

First Posted (Actual)

August 21, 2020

Study Record Updates

Last Update Posted (Estimate)

January 13, 2023

Last Update Submitted That Met QC Criteria

January 12, 2023

Last Verified

October 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

3
Subscribe